Detalles de la búsqueda
1.
Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance.
Nature
; 623(7989): 1053-1061, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37844613
2.
Metabolomic changes of the multi (-AGC-) kinase inhibitor AT13148 in cells, mice and patients are associated with NOS regulation.
Metabolomics
; 16(4): 50, 2020 04 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-32285223
3.
First-in-Human Study of AT13148, a Dual ROCK-AKT Inhibitor in Patients with Solid Tumors.
Clin Cancer Res
; 26(18): 4777-4784, 2020 09 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32616501
4.
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non-BRCA1/2-Mutant Cancers.
Cancer Discov
; 10(10): 1528-1543, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32532747
5.
A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors.
Clin Cancer Res
; 23(19): 5981-5992, 2017 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28645941
6.
First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer.
Clin Cancer Res
; 20(23): 5908-17, 2014 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25231405
7.
Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers.
Clin Cancer Res
; 20(22): 5672-85, 2014 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-25239610
Resultados
1 -
7
de 7
1
Próxima >
>>